Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$7.09MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Venker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 315
- Beta
- 0.81
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 31.39
Financials
Revenue
$7.09M+0.0%Net Income
$-153.22MEBITDA
$-153.13MFree Cash Flow
$-124.41MEPS (diluted)
$-0.75Shares Outstanding (diluted)
205.55M+1955.5%Operating Expenses
$160.32MCash & Debt
$797.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-505.61M | $-2.77 |
| 2025 | $0.00 | $-413.84M | $-2.73 |
| 2024 | $0.00 | $-259.34M | $-1.88 |
| 2023 | $0.00 | $-210.96M | $-1.71 |
| 2022 | $0.00 | $-156.73M | $-1.43 |
| 2021 | $0.00 | $-107.43M | $-1.22 |
| 2020 | $0.00 | $-66.39M | $-1.54 |
| 2019 | $0.00 | $-448.00 | $-0.00 |
| 2018 | $0.00 | $-136.74M | $-13.68 |
Valuation
IMVThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (4)
- Newszacks.com·11d ago·Negative
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improve…
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in impr…
View source ↗ - News (RSS)investing·54d ago·Neutral
Immunovant stock hits 52-week high at 41.37 USD
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.73 per share
Typical surprise -1.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.75 vs $-0.63miss
- Wed, May 20$-0.73 vs $-0.59miss
- Fri, Feb 6$-0.61 vs $-0.72beat
- Mon, Nov 10$-0.73 vs $-0.72miss
- Mon, Aug 11$-0.60 vs $-0.69beat
- Thu, May 29$-0.64 vs $-0.71beat
Estimates and results for IMVT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMVT officers and directors.
- Bought
- $350.0m
- Sold
- $14.7m
1 trade
49 trades
- Van Tuyl Christophersold
- Pande Atulsold
- Gloria Melaniesold
- Pande Atulsold
- Girao Tiagosold
- Stout Jay Ssold
- Gloria Melaniesold
- Gloria Melaniesold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMVT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.